| Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab) (NCT05320159) | Novartis Pharmaceuticals | 2021-02-03 |
| Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis (NCT04396366) | Novartis Pharmaceuticals | 2021-02-02 |
| Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT04079231) | Novartis Pharmaceuticals | 2021-02-01 |
| Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C (NCT04666298) | Novartis Pharmaceuticals | 2021-01-29 |
| Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (NCT04652726) | Novartis Pharmaceuticals | 2021-01-27 |
| Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies (NCT04648930) | Novartis Pharmaceuticals | 2021-01-27 |
| A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration (NCT04239027) | Novartis Pharmaceuticals | 2021-01-26 |
| Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (NCT04578834) | Novartis Pharmaceuticals | 2021-01-25 |
| Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (NCT04558918) | Novartis Pharmaceuticals | 2021-01-25 |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer (NCT04544189) | Novartis Pharmaceuticals | 2021-01-20 |
| Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer (NCT05982886) | Novartis Pharmaceuticals | 2021-01-15 |
| A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab (NCT04667117) | Novartis Pharmaceuticals | 2021-01-14 |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer (NCT04524000) | Novartis Pharmaceuticals | 2021-01-08 |
| Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome (NCT04541589) | Novartis Pharmaceuticals | 2021-01-05 |
| Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection (NCT04666272) | Novartis Pharmaceuticals | 2020-12-31 |
| Secukinumab Open Label Roll-over Extension Protocol (NCT04638647) | Novartis Pharmaceuticals | 2020-12-22 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria (NCT04300309) | Novartis Pharmaceuticals | 2020-12-21 |
| Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment (NCT04632927) | Novartis Pharmaceuticals | 2020-12-21 |
| Russian Registry of Patients With nAMD (NCT04935411) | Novartis Pharmaceuticals | 2020-12-20 |
| Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (NCT04641442) | Novartis Pharmaceuticals | 2020-12-18 |
| Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions (NCT04656223) | Novartis Pharmaceuticals | 2020-12-17 |
| An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (NCT04597632) | Novartis Pharmaceuticals | 2020-12-16 |
| Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (NCT04264819) | Novartis Pharmaceuticals | 2020-12-14 |
| Atrasentan in Patients With IgA Nephropathy (NCT04573478) | Novartis Pharmaceuticals | 2020-12-11 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients (NCT04635800) | Novartis Pharmaceuticals | 2020-12-10 |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) (NCT05349201) | Novartis Pharmaceuticals | 2020-12-09 |
| An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source (NCT05368818) | Novartis Pharmaceuticals | 2020-12-07 |
| Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis. (NCT05576779) | Novartis Pharmaceuticals | 2020-12-03 |
| Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation (NCT05611216) | Novartis Pharmaceuticals | 2020-12-01 |
| Study of Select Combinations in Adults With Myelofibrosis (NCT04283526) | Novartis Pharmaceuticals | 2020-11-30 |
| A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation (NCT04582409) | Novartis Pharmaceuticals | 2020-11-30 |
| Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. (NCT05421104) | Novartis Pharmaceuticals | 2020-11-27 |
| Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy (NCT04516369) | Novartis Pharmaceuticals | 2020-11-24 |
| Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL. (NCT05448872) | Novartis Pharmaceuticals | 2020-11-23 |
| Crizanlizumab Pregnancy Outcomes Intensive Monitoring (NCT07554547) | Novartis Pharmaceuticals | 2020-11-15 |
| Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM) (NCT04491136) | Novartis Pharmaceuticals | 2020-11-11 |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases (NCT04460729) | Novartis Pharmaceuticals | 2020-11-11 |
| Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (NCT04543331) | Novartis Pharmaceuticals | 2020-11-05 |
| A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting (NCT05787236) | Novartis Pharmaceuticals | 2020-11-05 |
| Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (NCT04328727) | Novartis Pharmaceuticals | 2020-11-04 |
| An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (NCT04488185) | Novartis Pharmaceuticals | 2020-11-02 |
| Special Drug Use-results Surveillance of Tabrecta Tablets (NCT04575025) | Novartis Pharmaceuticals | 2020-11-02 |
| Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (NCT04417621) | Novartis Pharmaceuticals | 2020-10-30 |
| Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment (NCT04587622) | Novartis Pharmaceuticals | 2020-10-30 |
| Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (NCT04593927) | Novartis Pharmaceuticals | 2020-10-28 |
| Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India (NCT04735354) | Novartis Pharmaceuticals | 2020-10-27 |
| Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) (NCT04225676) | Novartis Pharmaceuticals | 2020-10-19 |
| A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis (NCT04486716) | Novartis Pharmaceuticals | 2020-10-19 |
| Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (NCT04390763) | Novartis Pharmaceuticals | 2020-10-16 |
| Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis (NCT04480853) | Novartis Pharmaceuticals | 2020-10-12 |
| A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP (NCT04346654) | Novartis Pharmaceuticals | 2020-10-09 |
| A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease (NCT04391894) | Novartis Pharmaceuticals | 2020-10-06 |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (NCT04427072) | Novartis Pharmaceuticals | 2020-09-25 |
| Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) (NCT05488613) | Novartis Pharmaceuticals | 2020-09-24 |
| Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (NCT04564053) | Novartis Pharmaceuticals | 2020-09-23 |
| Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis (NCT04064242) | Novartis Pharmaceuticals | 2020-09-23 |
| Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT04268823) | Novartis Pharmaceuticals | 2020-09-10 |
| Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma (NCT04410523) | Novartis Pharmaceuticals | 2020-09-09 |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (NCT04240704) | Novartis Pharmaceuticals | 2020-09-07 |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (NCT04150029) | Novartis Pharmaceuticals | 2020-09-01 |
| Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data (NCT05177406) | Novartis Pharmaceuticals | 2020-08-31 |
| Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD) (NCT04443907) | Novartis Pharmaceuticals | 2020-08-25 |
| A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC (NCT04452877) | Novartis Pharmaceuticals | 2020-08-19 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations (NCT04323436) | Novartis Pharmaceuticals | 2020-08-19 |
| Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) (NCT05366257) | Novartis Pharmaceuticals | 2020-08-17 |
| Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program (NCT05066685) | Novartis Pharmaceuticals | 2020-08-11 |
| Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria (NCT04513548) | Novartis Pharmaceuticals | 2020-08-05 |
| Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants (NCT06558097) | Novartis Pharmaceuticals | 2020-07-29 |
| PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus (NCT04300296) | Novartis Pharmaceuticals | 2020-07-27 |
| Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects (NCT04321252) | Novartis Pharmaceuticals | 2020-07-22 |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer (NCT04294160) | Novartis Pharmaceuticals | 2020-07-22 |
| Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (NCT04097379) | Novartis Pharmaceuticals | 2020-07-20 |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (NCT04208178) | Novartis Pharmaceuticals | 2020-07-16 |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) (NCT05146687) | Novartis Pharmaceuticals | 2020-07-15 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (NCT04353492) | Novartis Pharmaceuticals | 2020-07-14 |
| Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo (NCT05826028) | Novartis Pharmaceuticals | 2020-07-09 |
| Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis (NCT05344482) | Novartis Pharmaceuticals | 2020-07-09 |
| Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (NCT04181762) | Novartis Pharmaceuticals | 2020-07-07 |
| Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities. (NCT05375097) | Novartis Pharmaceuticals | 2020-07-03 |
| Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France (NCT05964946) | Novartis Pharmaceuticals | 2020-06-24 |
| Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden (NCT05611229) | Novartis Pharmaceuticals | 2020-06-16 |
| Study of Efficacy and Safety of MAS825 in Patients With COVID-19 (NCT04382651) | Novartis Pharmaceuticals | 2020-06-11 |
| Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib (NCT04285723) | Novartis Pharmaceuticals | 2020-06-09 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (NCT04266301) | Novartis Pharmaceuticals | 2020-06-08 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (NCT04251533) | Novartis Pharmaceuticals | 2020-06-08 |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (NCT03628053) | Novartis Pharmaceuticals | 2020-06-05 |
| Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) (NCT04147195) | Novartis Pharmaceuticals | 2020-06-04 |
| Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study) (NCT05082415) | Novartis Pharmaceuticals | 2020-06-03 |
| A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data (NCT05096143) | Novartis Pharmaceuticals | 2020-06-03 |
| The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. (NCT04408937) | Novartis Pharmaceuticals | 2020-05-29 |
| Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia (NCT04382053) | Novartis Pharmaceuticals | 2020-05-27 |
| Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant (NCT03774082) | Novartis Pharmaceuticals | 2020-05-20 |
| Impact of Fingolimod Adherence on Outcomes (NCT05141669) | Novartis Pharmaceuticals | 2020-05-18 |
| Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (NCT04362137) | Novartis Pharmaceuticals | 2020-05-02 |
| Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease (NCT04358081) | Novartis Pharmaceuticals | 2020-05-01 |
| Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (NCT04362813) | Novartis Pharmaceuticals | 2020-04-30 |
| A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors (NCT05141240) | Novartis Pharmaceuticals | 2020-04-15 |
| Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models (NCT05096039) | Novartis Pharmaceuticals | 2020-04-10 |
| Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab (NCT04210843) | Novartis Pharmaceuticals | 2020-04-08 |
| Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa (NCT04179175) | Novartis Pharmaceuticals | 2020-03-18 |